ASST Capital Unveils the Aurora Quantitative System with Unprecedented 81% Prediction Accuracy
Exclusive Interview with ASST Capital's Quant Team on the Future of AI-Powered Investing
Colorado Springs, CO - In a major leap forward for quantitative investing, ASST Capital has announced the final testing phase of its groundbreaking Aurora Quantitative System, boasting an 81% prediction accuracy. With an official launch expected within five months, this AI-powered system is poised to reshape market intelligence by making institutional-grade trading insights accessible to everyday investors.
ASST Capital's quantitative team shared exclusive insights into the development and advantages of this revolutionary system.
AI-Driven Market Intelligence: A New Era for Investors
'The Aurora Quantitative System is a game-changer because it eliminates the emotional biases that impact traditional investing,' said ASST Capital's Quant Team Lead. 'Unlike strategies driven by market sentiment or personal experience, Aurora leverages big data, AI-driven modeling, and algorithmic trading to deliver precise, data-backed investment signals.'
Among its standout features, Aurora's Institutional Capital Tracking System enables real-time monitoring of major capital flows, helping investors decode the buying and selling behaviors of hedge funds and institutions—a level of insight traditionally reserved for elite traders.
How Did Aurora Achieve 81% Prediction Accuracy?
ASST Capital attributes Aurora's high accuracy to six months of AI training and rigorous backtesting across multiple asset classes, including stocks, cryptocurrencies, forex, and commodities.
'Our model has been trained on millions of simulated trades across different market conditions,' the Quant Team Lead explained. 'It doesn't just predict price movements—it integrates capital flows, market sentiment, and macroeconomic indicators, allowing for dynamic strategy adjustments during volatile periods.'
Who Can Benefit from the Aurora Quantitative System?
Designed to democratize quantitative trading, Aurora bridges the gap between institutional and retail investors.
Short-term traders gain access to real-time, AI-driven asset recommendations to capitalize on market trends.
Long-term investors can benefit from automated portfolio management, with AI-powered adjustments based on risk preferences.
'The biggest challenge for retail investors has always been access to institutional-grade tools. Aurora levels the playing field,' added the Quant Team Lead.
Countdown to Global Launch
Aurora is in its final optimization phase, with ASST Capital refining user experience and system stability before its global rollout.
'The future of trading is data-driven and AI-powered. Aurora will be one of the most intelligent and user-friendly trading platforms available—helping investors of all experience levels make informed, precise investment decisions,' ASST Capital's Quant Team Lead concluded.
About ASST Capital
ASST Capital is a leading innovator in quantitative trading and AI-driven financial technology. With a mission to democratize institutional-grade market insights, ASST Capital continues to push the boundaries of data-driven investing.
Media Contact:
Alexander Whitmore
ASST Capital
Email: aia@aiasst.com
102 S Tejon St Downtown, Suite 1100, Colorado Springs, CO 80903, United States
Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.
Media Contact
Company Name: ASST Capital
Contact Person: Alexander Whitmore
Email: Send Email
City: Colorado Springs
State: CO
Country: United States
Website: https://aiasst.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
a day ago
- Cision Canada
Aurora Expands Medical Cannabis Offerings in Australia with the Launch of IndiMed TEMPO 22
NASDAQ| TSX: ACB Canada's Largest Medical Cannabis Company Adds Two New Cultivars to Popular Brand Portfolio in the Australian Market EDMONTON, AB, June 5, 2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, has expanded their popular IndiMed brand with the launch of IndiMed TEMPO 22, available through the company's subsidiary, MedReleaf Australia. With the same consistent quality and reliable supply, this new 22% THC potency creates a greater range of treatment options available to prescribers. "Expanding our portfolio in the value segment in Australia reinforces our commitment to meet increasingly diversified patient needs with accessible, high-quality medical cannabis options," said Andre Jerome, Executive Vice President of Global Business Development at Aurora. "As a global leader in medical cannabis, we're proud to offer a diverse range of products that reflect both local demand and our dedication to innovation worldwide." IndiMed remains one of the most prescribed medical cannabis brands for patients in Australia. The two new cultivars available include: IndiMed TEMPO 22 | Lemon Laser – Sativa, 22% THC, <1% CBD, Dried Cannabis (15g) IndiMed TEMPO 22 | Pickled Petrol – Indica, 22% THC, <1% CBD, Dried Cannabis (15g) Aurora's continued focus on international growth and deep commitment to providing patients with innovative products and expanded access enables the company to maintain its global leadership position. MedReleaf Australia, a wholly owned subsidiary of Aurora, is committed to quality and proudly meeting all TGA-GMP standards. For further information about the company's offerings, doctors and health care professionals can contact MedReleaf Australia's clinical support team or visit their website: About Aurora Cannabis Inc. Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at and follow us on X and LinkedIn. Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB". Contact For Investors: ICR, Inc. | [email protected] Forward Looking Information This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law (" forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding: the expansion of the Company's medical cannabis offerings in Australia and the availability of specific products; the Company's commitment to innovation, quality and expanded access; the Company's continued focus on international growth; and the Company's global leadership position. These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at and filed with and available on the SEC's website at The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
Cision Canada
2 days ago
- Cision Canada
Xanadu Unveils First On-Chip Error-Resistant Photonic Qubit
TORONTO, June 4, 2025 /CNW/ - Xanadu has achieved a significant milestone in the development of scalable quantum hardware by generating error-resistant photonic qubits on an integrated chip platform. A foundational result in Xanadu's roadmap, this first-ever demonstration of such qubits on a chip is now published in Nature. This breakthrough builds on Xanadu's recent announcement of the Aurora system, which demonstrated—for the first time—all key components required to build a modular, networked, and scalable photonic quantum computer. With this latest demonstration of robust qubit generation using silicon-based photonic chips, Xanadu further strengthens the scalability pillar of its architecture. The quantum states produced in this experiment, known as GKP states, consist of superpositions of many photons to encode information in an error-resistant manner—an essential requirement for future fault-tolerant quantum computers. These states allow logic operations to be performed using deterministic, room-temperature-compatible techniques, and they are uniquely well-suited for networking across chips using standard fiber connections. This demonstration of generating photonic qubits was enabled by a number of key technological achievements from Xanadu's hardware team. These include the development of photon-number-resolving detectors with detection efficiencies above 99%, the fabrication of customized ultra-low loss silicon nitride waveguides on 300 mm wafer platforms, and the implementation of in-house state-of-the-art optical packaging. "GKP states are, in a sense, the optimal photonic qubit, since they enable logic gates and error correction at room temperature and using relatively straightforward, deterministic operations," says Zachary Vernon, CTO of Hardware at Xanadu. "This demonstration is an important empirical milestone showing our recent successes in loss reduction and performance improvement across chip fabrication, component design, and detector efficiency." The next hurdle towards a utility-scale photonic quantum computer remains clear: further reduction of optical loss will allow for higher quality GKP states suitable for fault-tolerance. With another significant milestone in its hardware roadmap complete, Xanadu remains focused on further optimizing fabrication and photonics packaging processes to alleviate optical loss across its platform. About Xanadu: Xanadu is a Canadian quantum computing company with the mission to build quantum computers that are useful and available to people everywhere. Founded in 2016, Xanadu has become one of the world's leading quantum hardware and software companies. The company also leads the development of PennyLane, an open-source software library for quantum computing and application development. Visit or follow us on X @XanaduAI.
Cision Canada
3 days ago
- Cision Canada
Aurora Cannabis to Host Fourth Quarter and Fiscal Year 2025 Investor Conference Call and File Related Year End Information
NASDAQ| TSX: ACB EDMONTON, AB, June 3, 2025 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and fiscal year 2025 on Wednesday, June 18, 2025 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the fourth quarter fiscal year 2025 before the opening of markets that same day. Conference Call Details Miguel Martin, Executive Chairman and Chief Executive Officer, and Simona King, Chief Financial Officer, will host the conference call and question and answer period. This weblink has also been posted to the Company's "Investor Info" link at under "Events". About Aurora Cannabis Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult- use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at and follow us on X and LinkedIn. Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB". Forward Looking Statements This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the timing of the release of the Company's financial statements for fourth quarter and fiscal year ended March 31, 2025 and scheduling of the conference call to discuss results. These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the timing, magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at and filed with and available on the SEC's website at The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
